See more : Ebara Corporation (6361.T) Income Statement Analysis – Financial Results
Complete financial analysis of Soligenix, Inc. (SNGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Soligenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Subaru Corporation (FUJHF) Income Statement Analysis – Financial Results
- Skanska AB (publ) (SKBSY) Income Statement Analysis – Financial Results
- Lu Thai Textile Co., Ltd. (000726.SZ) Income Statement Analysis – Financial Results
- Oceaneering International, Inc. (0KAN.L) Income Statement Analysis – Financial Results
- China Evergrande Group (EV1.F) Income Statement Analysis – Financial Results
Soligenix, Inc. (SNGX)
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 839.36K | 948.91K | 824.27K | 2.36M | 4.63M | 5.24M | 5.43M | 10.45M | 8.77M | 7.04M | 3.22M | 3.14M | 7.66M | 1.95M | 2.82M | 2.31M | 1.26M | 2.31M | 3.08M | 997.48K | 83.82K | 0.00 | 0.00 | 0.00 | 1.00 | 200.00K | 100.00K | 0.00 |
| Cost of Revenue | 742.05K | 550.82K | 728.64K | 1.82M | 3.57M | 4.60M | 4.31M | 8.43M | 6.88M | 5.31M | 2.54M | 2.59M | 2.11M | 1.64M | 1.48M | 1.89M | 943.39K | 1.97M | 2.07M | 936.64K | 76.20K | 0.00 | 0.00 | 0.00 | -1.41M | -1.70M | -500.00K | 0.00 |
| Gross Profit | 97.31K | 398.09K | 95.63K | 538.50K | 1.06M | 643.73K | 1.12M | 2.02M | 1.89M | 1.73M | 679.87K | 551.55K | 5.55M | 309.23K | 1.33M | 423.83K | 314.63K | 347.95K | 1.01M | 60.85K | 7.62K | 0.00 | 0.00 | 0.00 | 1.41M | 1.90M | 600.00K | 0.00 |
| Gross Profit Ratio | 11.59% | 41.95% | 11.60% | 22.82% | 22.95% | 12.28% | 20.66% | 19.29% | 21.51% | 24.55% | 21.09% | 17.54% | 72.49% | 15.88% | 47.31% | 18.35% | 25.01% | 15.04% | 32.80% | 6.10% | 9.09% | 0.00% | 0.00% | 0.00% | 140,775,100.00% | 950.00% | 600.00% | 0.00% |
| Research & Development | 3.31M | 7.94M | 8.39M | 15.15M | 8.12M | 6.75M | 5.51M | 4.30M | 5.40M | 5.09M | 5.07M | 2.61M | 6.27M | 5.68M | 4.52M | 1.73M | 3.10M | 4.62M | 3.68M | 3.66M | 2.73M | 2.94M | 2.47M | 956.74K | 2.03M | 3.10M | 1.80M | 906.46K |
| General & Administrative | 4.48M | 6.69M | 4.85M | 3.98M | 3.48M | 2.95M | 3.21M | 3.43M | 3.60M | 3.40M | 2.77M | 2.56M | 0.00 | 2.50M | 2.86M | 2.15M | 0.00 | 0.00 | 0.00 | 0.00 | 2.51M | 1.97M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 68.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.48M | 6.69M | 4.85M | 3.98M | 3.48M | 2.95M | 3.21M | 3.43M | 3.60M | 3.40M | 2.77M | 2.63M | 2.24M | 2.50M | 2.86M | 2.15M | 3.54M | 3.11M | 2.16M | 2.32M | 2.51M | 2.99M | 1.97M | 2.10M | 3.05M | 3.50M | 1.50M | 317.24K |
| Other Expenses | 0.00 | -132.87K | -174.77K | -95.36K | -433.59K | 0.00 | 0.00 | 3.43M | 3.60M | 3.40M | 2.77M | 2.63M | 2.24M | 0.00 | 0.00 | 0.00 | 3.54M | 3.93M | 2.16M | 2.32M | 2.51M | 2.99M | 12.15M | 2.10M | 4.45M | 5.20M | 2.00M | 0.00 |
| Operating Expenses | 7.80M | 14.50M | 13.06M | 19.03M | 11.17M | 9.70M | 8.72M | 7.72M | 9.00M | 8.49M | 7.84M | 5.24M | 8.51M | 8.19M | 7.38M | 3.88M | 6.64M | 8.55M | 5.84M | 5.98M | 5.23M | 5.93M | 14.63M | 3.06M | 6.48M | 8.30M | 3.80M | 1.26M |
| Cost & Expenses | 8.54M | 15.05M | 13.79M | 20.85M | 14.74M | 14.30M | 13.03M | 16.16M | 15.88M | 13.80M | 10.38M | 7.84M | 10.62M | 9.83M | 8.87M | 5.77M | 7.59M | 10.51M | 7.91M | 6.91M | 5.31M | 5.93M | 14.63M | 3.06M | 5.08M | 6.60M | 3.30M | 1.26M |
| Interest Income | 0.00 | 822.61K | 904.50K | 10.88K | 148.97K | 159.01K | 29.91K | 0.00 | 0.00 | 1.31K | 1.96K | 6.20K | 7.44K | 12.07K | 21.92K | 37.07K | 164.85K | 41.51K | 114.79K | 66.54K | 28.71K | 105.68K | 424.03K | 747.07K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 49.13K | 822.61K | 862.58K | 10.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 742.00 | 2.68K | 3.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -35.84K | -35.84K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.55K | 137.28K | 150.45K | 193.04K | 177.56K | 44.06K | 68.56K | 89.93K | 247.46K | 245.79K | 230.07K | 230.63K | 226.03K | 185.70K | 175.60K | 149.18K | 119.57K | 137.04K | 194.28K | 302.45K | 226.14K | 345.50K | 188.53K | 156.86K | 1.41M | 1.70M | 500.00K | 204.46K |
| EBITDA | -7.85M | -14.11M | -12.23M | -18.23M | -9.36M | -9.01M | -7.53M | -5.62M | -6.86M | -6.52M | -6.93M | -4.45M | -2.73M | -7.45M | -5.86M | -3.31M | -6.21M | -8.02M | -4.64M | -5.61M | -5.00M | -6.45M | -3.86M | -2.90M | -3.67M | -4.80M | -2.70M | -1.06M |
| EBITDA Ratio | -935.58% | -1,483.34% | -1,565.17% | -781.06% | -216.96% | -171.99% | -138.52% | -72.27% | -64.56% | -84.51% | -101.47% | -141.83% | -35.58% | -394.36% | -208.57% | -143.13% | -493.33% | -313.28% | -150.88% | -562.94% | -5,934.78% | 0.00% | 0.00% | 0.00% | -80,576,000.00% | 5,250.00% | -2,900.00% | 0.00% |
| Operating Income | -7.70M | -14.11M | -12.97M | -18.49M | -10.11M | -9.06M | -7.59M | -5.71M | -7.11M | -10.76M | -7.16M | -4.69M | -2.96M | -7.88M | -6.05M | -3.46M | -6.33M | -8.20M | -4.84M | -5.92M | -5.23M | -5.93M | -14.63M | -3.06M | -5.08M | -6.40M | -3.20M | -1.26M |
| Operating Income Ratio | -917.12% | -1,486.55% | -1,573.05% | -783.71% | -218.31% | -172.83% | -139.79% | -54.64% | -81.09% | -152.79% | -221.97% | -149.16% | -38.63% | -404.51% | -214.89% | -149.59% | -502.94% | -354.50% | -157.20% | -593.21% | -6,236.06% | 0.00% | 0.00% | 0.00% | -507,562,800.00% | -3,200.00% | -3,200.00% | 0.00% |
| Total Other Income/Expenses | -210.59K | -714.37K | -449.60K | 61.09K | 574.75K | 159.01K | 29.91K | 1.93M | -1.21M | 3.44M | -3.65M | 6.20K | 7.44K | 246.03K | 16.84K | 33.80K | 162.44K | 36.20K | 114.79K | 45.54K | -61.65K | -5.92K | -5.92K | -2.43M | -2.86M | -15.20M | 200.00K | 74.85K |
| Income Before Tax | -7.91M | -14.95M | -13.42M | -18.53M | -9.97M | -8.90M | -7.56M | -3.78M | -8.32M | -7.32M | -10.81M | -4.68M | -2.95M | -7.63M | -6.05M | 0.00 | -6.33M | -9.02M | 0.00 | -5.92M | -5.29M | -14.63M | -14.63M | -5.49M | -7.94M | -21.60M | -3.00M | -1.19M |
| Income Before Tax Ratio | -942.21% | -1,575.84% | -1,627.59% | -785.16% | -215.26% | -169.80% | -139.23% | -36.13% | -94.89% | -103.99% | -335.26% | -148.97% | -38.53% | -391.88% | -214.97% | 0.00% | -503.05% | -389.79% | 0.00% | -593.15% | -6,309.62% | 0.00% | 0.00% | 0.00% | -793,774,600.00% | -10,800.00% | -3,000.00% | 0.00% |
| Income Tax Expense | -1.77M | -1.15M | -864.74K | -836.89K | -610.68K | 159.01K | -416.81K | -530.14K | -488.93K | -616.87K | -750.36K | -521.46K | -574.16K | -245.81K | -16.84K | -33.80K | -162.44K | -36.20K | -114.79K | -45.54K | 61.65K | -965.43K | 5.92K | 1.74M | 2.43M | 15.40M | 0.00 | 0.00 |
| Net Income | -6.14M | -13.80M | -12.55M | -17.69M | -9.36M | -8.90M | -7.15M | -3.25M | -7.83M | -6.71M | -10.06M | -4.16M | -2.38M | -7.39M | -6.03M | -3.42M | -6.16M | -8.16M | -4.72M | -5.87M | -5.29M | -4.97M | -14.63M | -4.80M | -7.50M | -21.80M | -3.20M | -1.19M |
| Net Income Ratio | -731.60% | -1,454.12% | -1,522.68% | -749.69% | -202.07% | -169.80% | -131.56% | -31.06% | -89.31% | -95.23% | -311.99% | -132.39% | -31.04% | -379.26% | -214.29% | -148.12% | -490.03% | -352.93% | -153.47% | -588.64% | -6,309.62% | 0.00% | 0.00% | 0.00% | -750,101,900.00% | -10,900.00% | -3,200.00% | 0.00% |
| EPS | -12.66 | -76.96 | -75.06 | -154.45 | -115.88 | -162.09 | -279.17 | -223.73 | -721.04 | 0.00 | 0.00 | -56.07 | -32.56 | -109.48 | -108.07 | -100.77 | -203.93 | -384.10 | -284.78 | -433.58 | -543.70 | -662.23 | -3.26K | -1.18K | -2.09K | -6.57K | -3.06K | -703.37 |
| EPS Diluted | -12.66 | -76.89 | -75.06 | -154.45 | -115.88 | -162.09 | -279.17 | -320.56 | -721.04 | 0.00 | 0.00 | -56.07 | -32.56 | -109.48 | -108.07 | -100.77 | -203.93 | -384.10 | -284.78 | -433.58 | -543.70 | -662.23 | -3.26K | -1.18K | -2.09K | -6.57K | -3.06K | -703.37 |
| Weighted Avg Shares Out | 484.88K | 179.29K | 167.22K | 114.53K | 80.74K | 54.91K | 25.60K | 10.12K | 10.86K | 0.00 | 0.00 | 74.24K | 73.05K | 67.47K | 55.84K | 33.96K | 30.23K | 21.25K | 16.58K | 13.54K | 9.73K | 7.50K | 4.48K | 4.06K | 3.59K | 3.32K | 1.05K | 1.69K |
| Weighted Avg Shares Out (Dil) | 484.88K | 179.46K | 167.22K | 114.53K | 80.74K | 54.91K | 25.60K | 14.93K | 10.86K | 0.00 | 0.00 | 74.24K | 73.05K | 67.47K | 55.84K | 33.96K | 30.23K | 21.25K | 16.58K | 13.54K | 9.73K | 7.50K | 4.48K | 4.06K | 3.59K | 3.32K | 1.05K | 1.69K |
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
Significant Efficacy against Plaque Lesions Also Demonstrated with HyBryte™ PRINCETON, N.J. , Dec. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where...
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Phase 3 clinical study of HyBryte ™ in CTCL initiating in 2024 PRINCETON, N.J. , Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases...
Soligenix to Present at November 21st Virtual Investor Summit Microcap Event
PRINCETON, NJ / ACCESSWIRE / November 15, 2024 / Soligenix, Inc. (Nasdaq:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that...
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J. , Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results
PRINCETON, N.J. , Nov. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent...
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
Princeton, NJ, October 24, 2024 – PRISM MediaWire – Soligenix, Inc.
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that...
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of Psoriasis PRINCETON, N.J. , Oct. 22, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on...
Soligenix Invited to Present at Upcoming Investor Conferences
PRINCETON, N.J. , Oct. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the...
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
Two Presentations Highlight HyBryte™ Therapy's Improved Response Rates with Extended Treatment and Increased Light Doses PRINCETON, N.J. , Oct. 7, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
Source: https://incomestatements.info
Category: Stock Reports